Ordinary Shares, (pound).001 par value per share

Adaptimmune Therapeutics Plc

60 Jubilee Avenue, Abingdon, Oxfordshire, X0, OX14 4RX

New Enterprise Associates 14, L.P. ("NEA 14") and New Enterprise Associates 16, L.P. ("NEA 16" and collectively with NEA 14, the "Funds"); NEA Partners 14, L.P. ("NEA Partners 14"), which is the sole general partner of NEA 14, and NEA Partners 16, L.P. ("NEA Partners 16" and collectively with NEA Partners 14, the "GPLPs"), which is the sole general partner of NEA 16; NEA 14 GP, LTD ("NEA 14 GP"), which is the sole general partner of NEA Partners 14, and NEA 16 GP, LLC ("NEA 16 GP" and, collectively with the GPLPs and NEA 14 GP, the "Control Entities"), which is the sole general partner of NEA Partners 16; and Forest Baskett ("Baskett"), Anthony A. Florence, Jr. ("Florence"), Patrick J. Kerins ("Kerins"), Mohamad H. Makhzoumi ("Makhzoumi") and Scott D. Sandell ("Sandell") (together, the "Managers"). Baskett, Florence, and Sandell (the "Dual Managers") are directors of NEA 14 GP and managers of NEA 16 GP. Kerins is a director of NEA 14 GP (the "NEA 14 Director"). Florence, Makhzoumi, and Sandell are also members of the Executive Committee of NEA Management Company, LLC (the "Executive Committee"). The persons named in this Item 2 are referred to individually herein as a "Reporting Person" and collectively as the "Reporting Persons."

The address of the principal business office of the Funds, each Control Entity, Kerins and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Baskett and Makhzoumi is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, CA 94025. The address of the principal business office of Florence is New Enterprise Associates, 104 5th Avenue, 19th Floor, New York, NY 10011.

The principal business of each Fund is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Partners 14 is to act as the sole general partner of NEA 14. The principal business of NEA Partners 16 is to act as the sole general partner of NEA 16. The principal business of NEA 14 GP is to act as the sole general partner of NEA Partners 14. The principal business of NEA 16 GP is to act as the sole general partner of NEA Partners 16. The principal business of each of the Managers and the Executive Committee is to manage the Control Entities, the Funds and a number of affiliated partnerships with similar businesses.

During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Each of NEA 14 and NEA Partners 14 is a Cayman Islands exempted limited partnership. NEA 14 GP is a Cayman Islands exempted company. Each of NEA 16 and NEA Partners 16 is a Delaware limited partnership. NEA 16 GP is a limited liability company organized under the laws of the State of Delaware. Each of the Managers is a United States citizen.

As of August 18, 2025, NEA 14 is the record owner of 4 Ordinary Shares (the "NEA 14 Shares"). As the general partner of NEA 14, NEA Partners 14 may be deemed to own beneficially the NEA 14 Shares. As the sole general partner of NEA Partners 14, NEA 14 GP may be deemed to own beneficially the NEA 14 Shares. As directors of NEA 14 GP each of the Dual Managers and the NEA 14 Director may be deemed to own beneficially the NEA 14 Shares. As an individual member of the Executive Committee, which committee has been delegated certain approval rights with respect to dispositions of the NEA 14 Shares, Makhzoumi may also be deemed to own beneficially the NEA 14 Shares. As of August 18, 2025, NEA 16 is the record owner of 0 Ordinary Shares. Collectively, the Funds now hold a total of 4 Ordinary Shares (the "Firm Shares"). By virtue of their relationship as affiliated entities, whose controlling entities have substantially overlapping individual controlling persons, each of the Funds and the Control Entities may be deemed to share the power to direct the disposition and vote of the Firm Shares. Each Reporting Person disclaims beneficial ownership of the Firm Shares other than those shares which such person owns of record. The percentage of outstanding Ordinary Shares of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage was calculated for each Reporting Person based on the 1,590,309,546 Ordinary Shares reported by the Issuer to be outstanding as of August 11, 2025, on the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 13, 2025.

Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets (ii) shared power to vote or to direct the vote: See line 8 of cover sheets (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets.

Schedule A attached hereto as Exhibit 2 describes all transactions in the Issuer's Ordinary Shares that were effected by the Reporting Persons during the past 60 days.

No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, Ordinary Shares beneficially owned by any of the Reporting Persons.

August 15, 2025.